// App-Quantinova.ai

LB-258 : KEYNOTE-048 subgroup analysis

Researchers

Presenter

  • Barbara Burtness

Principal Investigators

  • Richard Greil

  • Denis Soulires

  • Makoto Tahara

  • Gilberto de Castro

  • Amanda Psyrri

  • Neus Bast

  • Prakash Neupane

  • se Bratland

  • Thorsten Fuereder

  • Brett G. Hughes

  • Ricard Mesia

  • Nuttapong Ngamphaiboon

  • Tamara Rordorf

  • Wan Zamaniah Wan Ishak

  • Joy Ge

  • Ramona Swaby

  • Burak Gumuscu

  • Kevin Harrington

Medical Centers

  • Yale University School of Medicine and Yale Cancer Center, New Haven, CT

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • National Cancer Center, EPOC, Chiba, Japan

  • Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, Brazil

  • National Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • University of Kansas Medical Center, Kansas City, MO

  • Oslo University Hospital, Oslo, Norway

  • Medical University of Vienna, Vienna, Austria

  • Royal Brisbane & Women's Hospital and University of Queensland, Brisbane, Australia

  • Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain

  • Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  • University of Zurich Hospital, Zurich, Switzerland

  • University of Malaya, Kuala Lumpur, Malaysia

  • Merck & Co., Inc., Kenilworth, NJ

  • Institute of Cancer ResearchRoyal Marsden National Institute for Health Research Biomedical Research Centre, London, United Kingdom

Locations

  • United States

  • Australia

  • Austria

  • Canada

  • Japan

  • Brazil

  • Greece

  • Spain

  • Norway

  • Thailand

  • Switzerland

  • Malaysia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02358031

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved